This article was originally published in Start Up
Chimerix Inc. is making headway on an oral drug that can be used to treat individuals exposed to the smallpox virus and to treat side effects of the smallpox vaccination. This, as well as the company's future products, will be delivered via a proprietary platform that uses the body's fat transport system to get nucleotides and other drugs into cells.
You may also be interested in...
CombinatoRx's platform screens combinations of known drugs to find pairs that could deliver a one-two punch to diseases such as cancer and rheumatoid arthritis.
Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.
NutraGenomics Inc. is using a systems approach to identify diet-responsive genes and SNPs involved in chronic diseases such as Type 2 diabetes, obesity, atherosclerosis, and certain cancers, using proprietary mouse models to examine dietary effects on genes, proteins, transcription, and metabolism.